Clinical Trials
56 trialsENKTL
Sun Yat-sen University
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
The Affiliated Hospital of Xuzhou Medical University
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
Sun Yat-sen University
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Ruijin Hospital
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
The Whole-course Management of Pegaspargase in ENKTL
The First Affiliated Hospital with Nanjing Medical University
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients
ViGenCell Inc.
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia EspaƱola de DermatologĆa
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Zhejiang University
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Samsung Medical Center
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Ruijin Hospital
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
RUE-DDGP
Zhengzhou University
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Sun Yat-sen University
SPENT
Sun Yat-sen University
VIDL+ASCT
Samsung Medical Center
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
Zhengzhou University
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Beijing Tongren Hospital
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Beijing Tongren Hospital
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
Beijing Tongren Hospital
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Ruijin Hospital
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
Zhengzhou University
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma
Peking University
Tofacitinib Combined With Chidamide in R/R ENKTCL
Sichuan University
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
ChineseAMS
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
Sichuan University
Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma
Zhengzhou University
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
Peking University Cancer Hospital & Institute
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Peking University Cancer Hospital & Institute
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effectļ¼Pharmacokinetics, Pharmacodynamics and EB Virus Activation
Sun Yat-sen University
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Sun Yat-sen University
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
Sun Yat-sen University
CTTNKTL-I/II
Zhengzhou University
CTTNKTL-ā ¢/ā £
Zhengzhou University
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy
Sun Yat-sen University
MTN
Air Force Military Medical University, China
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Sun Yat-sen University
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
National Cancer Institute (NCI)